...
antx-img

AN2 Therapeutics Inc, Common Stock

ANTX

NSQ

$1.365

-$0.03

(-2.14%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$41.83M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
86.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.22
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.87 L
$22.22 H
$1.365

About AN2 Therapeutics Inc, Common Stock

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameANTXSectorS&P500
1-Week Return3.7%-0.4%-1.9%
1-Month Return0.72%-4.57%-0.37%
3-Month Return34.62%-10.14%4.19%
6-Month Return-32.37%-5.67%9.34%
1-Year Return-93.28%2.53%25.19%
3-Year Return-90.91%-0.39%26.48%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue---77.00K-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit---(77.00K)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-7700000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses5.18M7.28M21.57M42.26M69.64M[{"date":"2019-12-31","value":7.44,"profit":true},{"date":"2020-12-31","value":10.46,"profit":true},{"date":"2021-12-31","value":30.98,"profit":true},{"date":"2022-12-31","value":60.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(5.18M)(7.28M)(21.57M)(42.26M)(69.64M)[{"date":"2019-12-31","value":-517800000,"profit":false},{"date":"2020-12-31","value":-728400000,"profit":false},{"date":"2021-12-31","value":-2157400000,"profit":false},{"date":"2022-12-31","value":-4226200000,"profit":false},{"date":"2023-12-31","value":-6963500000,"profit":false}]
Total Non-Operating Income/Expense-(6.32M)100.00K2.66M-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-237.71,"profit":false},{"date":"2021-12-31","value":3.76,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(5.63M)(13.60M)(21.54M)(40.96M)(64.73M)[{"date":"2019-12-31","value":-563500000,"profit":false},{"date":"2020-12-31","value":-1360300000,"profit":false},{"date":"2021-12-31","value":-2154300000,"profit":false},{"date":"2022-12-31","value":-4095600000,"profit":false},{"date":"2023-12-31","value":-6473200000,"profit":false}]
Income Taxes(31.07K)(3.00K)(69.00K)514.00K(69.64K)[{"date":"2019-12-31","value":-6.04,"profit":false},{"date":"2020-12-31","value":-0.58,"profit":false},{"date":"2021-12-31","value":-13.42,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-13.55,"profit":false}]
Income After Taxes-(13.60M)(21.47M)(41.47M)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1360000000,"profit":false},{"date":"2021-12-31","value":-2147400000,"profit":false},{"date":"2022-12-31","value":-4147000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations-(13.60M)(21.54M)(40.96M)(59.68M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1360300000,"profit":false},{"date":"2021-12-31","value":-2154300000,"profit":false},{"date":"2022-12-31","value":-4095600000,"profit":false},{"date":"2023-12-31","value":-5967600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(5.63M)(13.60M)(21.47M)(41.47M)(64.73M)[{"date":"2019-12-31","value":-563500000,"profit":false},{"date":"2020-12-31","value":-1360000000,"profit":false},{"date":"2021-12-31","value":-2147400000,"profit":false},{"date":"2022-12-31","value":-4147000000,"profit":false},{"date":"2023-12-31","value":-6473200000,"profit":false}]
EPS (Diluted)---(4.71)(2.82)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-471,"profit":false},{"date":"2023-12-31","value":-282,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ANTX
Cash Ratio 9.33
Current Ratio 9.75

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANTX
ROA (LTM) -42.89%
ROE (LTM) -69.48%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANTX
Debt Ratio Lower is generally better. Negative is bad. 0.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.90

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANTX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.48
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is AN2 Therapeutics Inc share price today?

AN2 Therapeutics Inc (ANTX) share price today is $1.365

Can Indians buy AN2 Therapeutics Inc shares?

Yes, Indians can buy shares of AN2 Therapeutics Inc (ANTX) on Vested. To buy AN2 Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AN2 Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of AN2 Therapeutics Inc (ANTX) via the Vested app. You can start investing in AN2 Therapeutics Inc (ANTX) with a minimum investment of $1.

How to invest in AN2 Therapeutics Inc shares from India?

You can invest in shares of AN2 Therapeutics Inc (ANTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AN2 Therapeutics Inc shares
What is AN2 Therapeutics Inc 52-week high and low stock price?

The 52-week high price of AN2 Therapeutics Inc (ANTX) is $22.22. The 52-week low price of AN2 Therapeutics Inc (ANTX) is $0.87.

What is AN2 Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AN2 Therapeutics Inc (ANTX) is

What is AN2 Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AN2 Therapeutics Inc (ANTX) is 0.48

What is AN2 Therapeutics Inc dividend yield?

The dividend yield of AN2 Therapeutics Inc (ANTX) is 0.00%

What is the Market Cap of AN2 Therapeutics Inc?

The market capitalization of AN2 Therapeutics Inc (ANTX) is $41.83M

What is AN2 Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of AN2 Therapeutics Inc is ANTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top